Our Science
At LOTO Biotech Platform, our initiative to sell preclinical pharmaceutical molecules is designed to deliver a comprehensive range of benefits that enhance the customer experience. By offering scientific innovations, continuous support, personalized solutions, reduced time-to-market, flexible contracts, and access to research and training networks, our initiative not only meets but exceeds customer expectations, providing unexpected advantages that make the overall experience more enriching and rewarding.
Continuous Technical and Scientific Support
We provide ongoing technical and scientific support during the clinical development and pre-commercialization phases. This continuous assistance improves the effectiveness and efficiency of development projects, reducing both time and costs.
Reduced Time-to-Market
By offering molecules ready for the clinical phase, we significantly reduce the time required to bring a new drug to market. This accelerates the launch of new products, increasing the competitiveness of our pharmaceutical clients.
Flexible Licensing Contracts
Our flexible licensing contracts with milestones and royalties allow clients to minimize initial financial risk and proceed gradually based on the success of the development process.
Technological Consistency and Reduced Investment Risk
Drugs developed through our platform are based on the same formulation and mechanism of action, significantly reducing the investment risk associated with treating new pathologies. The proven efficacy and safety in existing treatments can be extended to new drugs with much lower uncertainty. This technological consistency not only fosters greater confidence among investors and commercial partners but also optimizes development processes, accelerating the time-to-market for new therapeutic indications.
Standardized Approach
Our standardized approach facilitates the integration of new drugs into existing corporate portfolios, reducing development costs and improving overall operational efficiency.
By leveraging our advanced in-silico technology and deep expertise, LOTO Biotech Platform is dedicated to transforming the pharmaceutical development landscape, providing innovative solutions that drive success for our clients and deliver better outcomes for patients worldwide.
Starting from Real World Data
LOTO positions itself in the diagnostics sector by identifying the best pharmaceutical candidates through access to genomic databases and information from patient associations.
The LOTO-Interfering Engine
The LOTO platform, which we have named LOTO-Interfering, is based on the use of in-silico technology, namely through machine learning and advanced computing, for the design of a group of innovative drugs based on small interfering RNA (siRNA) technology. These drugs are intended for the treatment of rare diseases caused by dominant negative (DN) genetic mutations. DNs are a type of genetic mutation where an altered version of a protein interferes with the function of the normal protein produced by the non-mutated allele. This effect can lead to a loss or alteration of protein function overall, often resulting in genetic diseases.
An Industrial Approach
Our platform approach to drug development at LOTO Biotech Platform leverages advanced in-silico technology, enabling the design of innovative siRNA-based drugs with a standardized formulation and mechanism of action. This consistency reduces the complexity and risk associated with developing treatments for new pathologies. By providing molecules ready for the clinical phase, we significantly cut down the time-to-market, allowing quicker transitions from development to market launch. Additionally, our continuous technical and scientific support throughout the clinical and pre-commercialization stages streamlines the development process, further reducing costs and enhancing overall efficiency in drug production, testing, and approval.
